DIFFERENCES IN BETA-AMYLOID (BETA/A4) DEPOSITION IN HUMAN PATIENTS WITH DOWNS-SYNDROME AND SPORADIC ALZHEIMERS-DISEASE

被引:22
|
作者
ARMSTRONG, RA
机构
[1] Vision Sciences, Aston University, Birmingham
关键词
DOWNS SYNDROME; ALZHEIMERS DISEASE; BETA/A4; DEPOSITION; AMYLOID PRECURSOR PROTEIN;
D O I
10.1016/0304-3940(94)90374-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The density of diffuse, primitive, classic and compact beta-amyloid (beta/A4) deposits was estimated in the hippocampus and adjacent gyri in human patients with Down's syndrome (DS) and sporadic Alzheimer's disease (AD). The objective of the study was to determine whether there were differences in beta/A4 deposition in DS and sporadic AD and whether these differences could be attributed to overexpression of the amyloid precursor gene (APP) in DS. Total beta/A4 deposit density was greater in DS than AD in all brain regions studied but the DS/AD density ratios varied between brain regions. In the majority of brain regions, the ratio of primitive to diffuse beta/A4 deposits was greater in DS but the ratio of classic to diffuse deposits was greater in AD. The data were consistent with the hypothesis that overexpression of the APP gene in DS may lead to increased beta/A4 deposition. However, local brain factors also appear to be important in beta/A4 deposition in DS. Overexpression of the APP gene may also be resposible for increased production of paired helical filaments (PHF) and result in enhanced formation of primitive beta/A4 deposits in DS. In addition, increased formation of classic deposits in AD suggests that factors necessary for the production of a compact amyloid core are enhanced in AD compared with DS.
引用
收藏
页码:133 / 136
页数:4
相关论文
共 50 条
  • [21] BETA-AMYLOID, PROTEIN PROCESSING AND ALZHEIMERS-DISEASE
    HAASS, C
    HUNG, AY
    CITRON, M
    TEPLOW, DB
    SELKOE, DJ
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1995, 45-1 (3A): : 398 - 402
  • [22] NEURODEGENERATION, ALZHEIMERS-DISEASE, AND BETA-AMYLOID TOXICITY
    HOYER, S
    LIFE SCIENCES, 1994, 55 (25-26) : 1977 - 1983
  • [23] ALZHEIMERS-DISEASE AND DOWNS-SYNDROME
    PRICE, DL
    WHITEHOUSE, PJ
    STRUBLE, RG
    COYLE, JT
    CLARK, AW
    DELONG, MR
    CORK, LC
    HEDREEN, JC
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1982, 396 (OCT) : 145 - 164
  • [24] THE ROLE OF BETA-AMYLOID IN THE DEVELOPMENT OF ALZHEIMERS-DISEASE
    II, K
    DRUGS & AGING, 1995, 7 (02) : 97 - 109
  • [25] THE ROLE OF BETA-AMYLOID PEPTIDE IN ALZHEIMERS-DISEASE
    LEBLANC, A
    METABOLIC BRAIN DISEASE, 1994, 9 (01) : 3 - 31
  • [26] HUMAN-ANTIBODIES REACTIVE WITH BETA-AMYLOID IN ALZHEIMERS-DISEASE
    GASKIN, F
    XU, S
    FINLEY, J
    JOURNAL OF IMMUNOLOGY, 1993, 150 (08): : A238 - A238
  • [27] BETA-AMYLOID IN ALZHEIMERS-DISEASE - THERAPEUTIC IMPLICATIONS
    POLLARD, HB
    ROJAS, E
    ARISPE, N
    CNS DRUGS, 1994, 2 (01) : 1 - 6
  • [28] ALZHEIMERS-DISEASE AND DOWNS-SYNDROME
    MANN, DMA
    HISTOPATHOLOGY, 1988, 13 (02) : 125 - 137
  • [29] FAMILIAL ALZHEIMERS-DISEASE - BETA-AMYLOID RESURRECTED
    WRIGHT, AF
    GOEDERT, M
    HASTIE, ND
    NATURE, 1991, 349 (6311) : 653 - 654
  • [30] NEURONAL AND MICROGLIAL INVOLVEMENT IN BETA-AMYLOID PROTEIN DEPOSITION IN ALZHEIMERS-DISEASE
    CRAS, P
    KAWAI, M
    SIEDLAK, S
    MULVIHILL, P
    GAMBETTI, P
    LOWERY, D
    GONZALEZDEWHITT, P
    GREENBERG, B
    PERRY, G
    AMERICAN JOURNAL OF PATHOLOGY, 1990, 137 (02): : 241 - 246